From Humira to Keytruda: The Blueprint for Surviving the Composition-of-Matter Cliff
If you work in pharma, youve felt it: the moment the calendar turns from pipeline optionality to patent reality. One day, youre planning launches. The next, youre star…

Pharmas patent cliff isnt just about expiration dates. Its about how those dates are engineered.
For years, the industry has treated method-of-use patents like a footnotesomething technical, something legal, something that happens in the background whi…

The Patent Dance Is Not a DanceIts a Deadline. Heres How Biosimilar Developers Actually Win (or Lose) Before Court Ever Opens.
If youve ever watched the patent dance play out in biosimilars, you might think its mostly legal theater: notices, exchanges,…

Most teams dont lose to competitorsthey lose to time.
In pharma, time isnt just a calendar problem. Its a patent problem. And if youre still waiting for legal notices, office actions, or late-stage signals to understand when exclusivity might endand …

Patent thickets arent just a legal inconveniencetheyre a market design problem. When a single products IP landscape becomes a maze of overlapping Orange Book listings, method-of-use claims, formulation patents, and ever-shifting litigation timelines, t…

Drug patents arent just about moleculestheyre about manufacturing.
For years, the industry has treated patent strategy as a game of chemical structures, claims charts, and the occasional late-night Markush tweak. But the real battleground for many bl…

Pharma boards dont fear litigation. They fear what litigation does to decisions.
When a patent case lands on the deskespecially one involving a blockbuster or a platform assetthe immediate question is usually legal: Who wins? But the board-level questi…

Generic drug developers dont lose to bad luck. They lose to design choices made too late.
If youre building a generic pipeline, formulation patents can feel like an ambush: you think youre competing on bioequivalence and manufacturing efficiencythen …

Pharma forensics is having a momentand its not because the science got easier.
In the last few years, the real battleground in drug competition has shifted from the headline active ingredient to the less glamorous, more defensible details: formulations…

Designing Around the Moat: What Generic Developers Should Know About Secondary Formulation Patents
In generic drug development, the real fight often isnt about the first patent. Its about what comes afterthose secondary formulation patents that sit lik…